Back to search results

Observational Study on Diabetes After Acute Pancreatitis

This observational study, called DREAM, is looking at how often diabetes develops after a person has acute pancreatitis (a sudden inflammation of the pancreas). Researchers want to understand why some people get diabetes after pancreatitis and what factors might play a role, such as age or how severe their pancreatitis was. They will also investigate if there's ongoing damage to the cells that make insulin, or if pancreatitis changes the immune system in a way that leads to diabetes. The study aims to follow 800 participants for 36 months. You might be able to join if you are between 18 and 75 years old and were diagnosed with acute pancreatitis within 90 days before enrolling. The study will measure if you develop diabetes after your acute pancreatitis episode.

Study design
This is an observational study with a planned enrollment of 800 participants. It is not a drug trial, but rather aims to understand how diabetes develops after acute pancreatitis.
What's involved
You would participate in all aspects of the study, including providing informed consent, completing forms, telephone interviews, metabolic testing (like oral glucose tolerance tests), and planned follow-up appointments.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 36 months to see if they develop diabetes after acute pancreatitis.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05197920

Diabetes RElated to Acute Pancreatitis and Its Mechanisms

Recruiting
Not specifiedAges 18–75Observational
Milton S. Hershey Medical Center
~800 participants
Updated 2025-11-18 on ClinicalTrials.gov

At a glance

Recruiting sites
13 of 13 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
diabetes mellitus (DM) following a qualifying episode of acute pancreatitis (AP)
Measured over any time during the 36-month longitudinal follow-up period

Conditions

Acute Pancreatitis

Explore related trials

Acute PancreatitisDiabetes Mellitus

Where it's being run

13 sites across 9 states
California3
Florida2
Illinois2
Indiana1
Maryland1
Minnesota1
Ohio1
Pennsylvania1

Study leadership

  • Vernon M Chinchilli, PhD · PRINCIPAL_INVESTIGATOR · Penn State College of Medicine
  • Dhiraj Yadav, MD, MPH · STUDY_CHAIR · University of Pittsburgh
  • Melena D Bellin, MD · STUDY_CHAIR · University of Minnesota
  • Phillip A Hart, MD · STUDY_CHAIR · Ohio State University

Who to contact

Melissa A Butt, DrPH
[email protected]
717-531-1258
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of acute pancreatitis (AP) 0-90 days prior to enrollment date
Participant fully understands and is able to participate in all aspects of the study, including providing informed consent, completion of case report forms (CRFs), telephone interviews, metabolic testing, and planned longitudinal follow-ups

Exclusion

Diagnosis of definite chronic pancreatitis (CP) at enrollment based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP): (a) Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular); (b) Intraductal filling defects suggestive of calcifications on MRI and/or MRCP
Potential participants with post-endoscopic retrograde cholangiopancreatography (post- ERCP) AP who are hospitalized for \<48 hours.
Prior (i.e., before enrollment) direct endoscopic necrosectomy of the pancreas or percutaneous necrosectomy or drainage of necrotic collection(s). Participants who require this during follow-up will remain in the study
Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and metastasis
Confirmed or suspected cystic tumor associated with main pancreatic duct dilation, or believed to be the cause of AP (in the site-PI's judgement)
Prior pancreatic surgery, including, but not limited to: distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, Frey procedure
Use of disallowed concomitant medications within 30 days prior to enrollment. A comprehensive list of disallowed medications will be included and routinely updated in the study's Manual of Procedures
Severe systemic illness that in the judgement of the investigative team will confound outcome assessments of DM and immunological outcomes or pose additional risk for harms, including: history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with estimate glomerular filtration rate (eGFR) \< 30 or on dialysis prior to AP, and cirrhosis (based on imaging or biopsy), or any other medical condition that in the opinion of the site-PI carries a life expectancy of \<12 months.
Known pregnancy at the time of enrollment. Participants who become pregnant during follow-up will remain in the study, but may have modified study assessments for safety
Incarceration
Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study

What this trial measures

  • diabetes mellitus (DM) following a qualifying episode of acute pancreatitis (AP)any time during the 36-month longitudinal follow-up period

    time to onset of DM during the 36-month longitudinal follow-up period